Previous 10 |
FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to File letters for the Company’s N...
Gainers: Indonesia (NYSE:INDO) +79%. Meritor (NYSE:MTOR) +45%. Ocugen (NASDAQ:OCGN) +22%. Datasea (NASDAQ:DTSS) +20%. IronNet (NYSE:IRNT) +20%. Riley Exploration Permian (NYSE:REPX) +19%. Arteris (NASDAQ:AIP) +17%. Houghton Mifflin Harcourt Company (NASDAQ:HMHC) +15%. MEDIROM Healthcare Techn...
Allarity Therapeutics (ALLR -31.0%), a clinical-stage biopharmaceutical company, is trading sharply lower in morning hours on Tuesday after announcing a regulatory setback in the U.S. for its experimental therapy dovitinib and DRP-Dovitinib companion diagnostic. The U.S. Food and Drug Adminis...
Gainers: HOOKIPA Pharma HOOK +18%. Nuvectis Pharma (NASDAQ:NVCT) +16%. Ocugen OCGN +14%. Privia Health (NASDAQ:PRVA) +12%. IMARA (NASDAQ:IMRA) +11%. Losers: Allarity Therapeutics (NASDAQ:ALLR) -29%. Homology Medicines FIXX -27%. Karyopharm The...
Refusal to File letters concern the new drug application for d ovitinib and the DRP ® -Dovitinib companion diagnostic pre-market approval application Allarity intends to seek guidance from the FDA on how to further advance dovitinib ...
Press release Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers , utilizing Allarity’s DRP® companion diagnostics Allarity has submitted a new drug...
News, Short Squeeze, Breakout and More Instantly...
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
Allarity Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the ...
Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity The...